Table 3

Multivariate analysis for estimation of the chemopreventive effect of metformin in diabetic patients by incremental years

Diabetic patients (N=47 820)ORs (95% CI)p Value
Metformin use (each incremental year)0.93 (0.91 to 0.94)<0.0001
Age (each incremental year)1.00 (1.00 to 1.00)0.8437
Gender (male vs female)1.03 (0.99 to 1.08)0.1629
Hepatitis B13.81 (12.61 to 15.13)<0.0001
Hepatitis C17.07 (15.57 to 18.71)<0.0001
Liver cirrhosis4.29 (3.61 to 5.10)<0.0001
End stage renal failure0.83 (0.77 to 0.89)<0.0001
DM duration (each incremental year)0.96 (0.95 to 0.96)<0.0001
DM control (each incremental visit per year)1.02 (1.02 to 1.03)<0.0001
Other OHA agents use (each incremental year)1.02 (1.01 to 1.04)0.0052
Thiazolidinediones use (each incremental year)0.91 (0.87 to 0.95)<0.0001
Insulin use (each incremental year)1.13 (1.10 to 1.16)<0.0001
  • DM, diabetes mellitus; OHA, oral hypoglycaemic agent.